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Figure 1. Two patients with grade 1a tumors based on the pathological assessment. (A and 
B): A 46-year-old man had a primary tumor in the lower esophagus. (A): Pre-treatment 
with 18F-fluordeoxyglucose positron emission tomography/computed tomography 
(PET/CT) shows a maximum standard uptake value (SUVmax) of 13.60 and a metabolic 
tumor volume (MTV) of 60.34. (B): The post-treatment PET/CT shows an SUVmax of 
21.35 and an MTV of 76.11. The reduction rate of the SUV is −57%, and that of the MTV 
is −26%. (C and D): A 66-year-old man with a primary tumor in the lower esophagus. 
(C): Pretreatment PET/CT shows an SUVmax of 21.51 and an MTV of 102.01. (D): Post-
treatment PET/CT shows an SUVmax of 2.25 and an MTV of 0. The reduction rate of the 
SUV is 89.5%, and the MTV is 100%. 
 
Figure 2. Spearman’s correlation coefficients for a primary tumor and lymph node 
metastasis. There is no correlation between (A) the %decrease in SUV after neoadjuvant 
chemotherapy NAC (R2=0.079) or (B) the %decrease in MTV after NAC (R2=0.123).
 
Figure 3. Kaplan–Meier analysis of the patients with a diagnosis of esophageal cancer. 
(A): The overall survival shows no significant difference between the %decrease in 
SUVmax of ≥30 and SUVmax <30. (B): Prediction of overall survival shows a significant 
difference between the %decrease in the MTV ≥30 and MTV <30. 
 
 
 
 
 
